0001104659-22-091487.txt : 20220815
0001104659-22-091487.hdr.sgml : 20220815
20220815203445
ACCESSION NUMBER: 0001104659-22-091487
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220811
FILED AS OF DATE: 20220815
DATE AS OF CHANGE: 20220815
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Guico-Pabia Christine J.
CENTRAL INDEX KEY: 0001887144
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37558
FILM NUMBER: 221168144
MAIL ADDRESS:
STREET 1: C/O NABRIVA THERAPEUTICS PLC
STREET 2: 414 COMMERCE DRIVE, SUITE 120
CITY: FORT WASHINGTON
STATE: PA
ZIP: 19034
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Nabriva Therapeutics plc
CENTRAL INDEX KEY: 0001641640
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 25-28 NORTH WALL QUAY
CITY: DUBLIN
STATE: L2
ZIP: D01 H104
BUSINESS PHONE: (610) 816-6640
MAIL ADDRESS:
STREET 1: 414 COMMERCE DRIVE
STREET 2: STE 120
CITY: FORT WASHINGTON
STATE: PA
ZIP: 19034
FORMER COMPANY:
FORMER CONFORMED NAME: Nabriva Therapeutics AG
DATE OF NAME CHANGE: 20150507
4
1
tm2222534-16_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2022-08-11
0
0001641640
Nabriva Therapeutics plc
NBRV
0001887144
Guico-Pabia Christine J.
414 COMMERCE DR.
SUITE 120
FORT WASHINGTON
PA
19034
0
1
0
0
Chief Medical Officer
Share Options
0.45
2022-08-11
4
M
0
71500
0
D
2032-01-27
Ordinary Shares
71500
0
D
Restricted Stock Units
2022-08-11
4
M
0
35700
0
D
Ordinary Shares
35700
0
D
Stock Appreciation Right
0.45
2022-08-11
4
M
0
71500
0
A
2032-01-27
Ordinary Shares
71500
71500
D
Phantom Shares
2022-08-11
4
M
0
35700
0
A
Ordinary Shares
35700
35700
D
The option was granted on January 28, 2022, subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 Annual General Meeting (the "2022 AGM") of Nabriva Therapeutics plc (the "Issuer"), the option would remain outstanding and convert into a cash-settled share appreciation right. On August 11, 2022, the Issuer held the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the option to convert to a cash-settled share appreciation right.
Subject to the reporting person's continued employment with the Issuer, the cash-settled share appreciation right will vest over a four-year period beginning January 28, 2023. Twenty-five percent (25%) of the cash-settled share appreciation right will vest on the one (1) year anniversary of the date of grant, and the remaining seventy-five percent (75%) of the cash-settled share appreciation right will vest on a monthly pro-rata basis over the remaining vesting period.
The restricted stock units ("RSU") were granted on January 28, 2022, and each RSU represented a contingent right to receive one ordinary share of the Issuer subject to shareholder approval; provided, that if such shareholder approval was not obtained at the 2022 AGM, then each RSU would represent the right to receive the economic equivalent of one ordinary share of the Issuer in cash on the applicable vesting date ( "Phantom Shares"). On August 11, 2022, the Issuer held it's the 2022 AGM, at which meeting the Issuer's shareholders did not approve an amendment to the Issuer's 2020 Share Incentive Plan, as amended, causing the RSU to convert to Phantom Shares.
Subject to the reporting person's continued employment with the Issuer, the Phantom Shares will vest in equal annual installments over four years with the first installment vesting on January 28, 2023.
/s/ J. Christopher Naftzger, power of attorney
2022-08-15